Foresee Genomics

Empowering small and medium-sized labs with fast, affordable, and accurate next-generation sequencing (NGS) solutions.

Health Tech & Life Sciences
Active
Seed Haifa, Israel Founded 2017
Last updated 2026-07-26
Total raised
$4.2M
Last: Undisclosed Round 2025-01
Stage
Seed
Founded
2017
Headcount
7
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

Foresee Genomics is an Israeli startup developing a DNA testing system for cancer patients, combining molecular biology and computational analysis. The company's mission is to make cutting-edge genomic testing accessible to all, particularly small and medium-sized laboratories, by providing cost-effective and high-precision NGS solutions. Their technology includes protocols, reagents, and bioinformatics tools to enable labs to perform genomic analysis independently, without the need for costly infrastructure or large sample requirements. Foresee Genomics aims to democratize access to advanced NGS technologies for all labs that may need critical, timely information for precision medicine and enhanced patient outcomes.

Funding history · 4 rounds · $4.2M total

4 events/rounds · $4.2M Total Funding: $2.9M in Private Equity, $1.3M in Debt
Dec 2021
Sep 2018
Seed $800K unknown
★ IBM★ MindUP★ Medtronic★ Rambam Medical Center★ Impact 1st Investments★ Pitango Venture Capital★ Israel Innovation Authority
Sep 2017
Grant $3K pitchbook.com
★ BizTEC★ Technion

Offices

Haifa, Israel · HQ / main office

Q&A

What is Foresee Genomics' primary mission?
Foresee Genomics aims to empower small and medium-sized laboratories with fast, affordable, and accurate next-generation sequencing (NGS) solutions for DNA testing in cancer patients.
When was Foresee Genomics founded?
Foresee Genomics was founded in August 2017.
How many employees does Foresee Genomics currently have?
Foresee Genomics has 1-10 employees.
What is the total amount of funding Foresee Genomics has raised to date?
Foresee Genomics has raised a total of $3,060,000.
When was Foresee Genomics' most recent funding round and who were the lead investors?
In January 2025, Foresee Genomics closed a SAFE round with.
What is Foresee Genomics' current funding stage?
Foresee Genomics is currently in the Seed funding stage.
Who is the Founder & CTO of Foresee Genomics?
Roi Feingersch is the Founder & CTO of Foresee Genomics.
In which country is Foresee Genomics headquartered?
Foresee Genomics is headquartered in Haifa, Israel.

Team · 8

Roi Feingersch
Founder · CTO & Founder
Margalit Tocher
CEO
Dvir Dahary
VP of Product Development
Benjamin Cohen
Senior Software Developer
Tal Havkin-Solomon
Senior Molecular Biologist
Assaf Livne
VP BD
Michal Brunwasser-Meirom
R&D Manager
Yosef Marovka
Bioinformatics and Data Science Advisor

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Platforms & InterfacesSoftwareBiologicalsGenes
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

healthcare-providersclinicspersonalizationdiagnosticshospitalsoncologydecision-makingcancerdigital-healthcarebiotechnologysaashematologyhardwaregenetic-disorders
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteforeseegenomics.com
LinkedInlinkedin.com/company/35666455

Identifiers & details

Legal nameForesee Genomics LTD
Founded2017-8
Employees (exact)7

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domainforeseegenomics.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515702579
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2017-08-07
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events2 — other (1), shares_capital (1)
Registered addressהדולב 3 בר-לב

Recent registry events

DateEvent
2025-10-21עדכון כתובת ו/או מען דיגיטלי
2025-07-15שינוי בהרכב הון - מניות-שינוי ערך נקוב